Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GC-rich DNA at Sp1 consensus promoter sites, commonly known as "GC boxes," are essential regulatory motifs located within the proximal promoter regions of a wide array of genes (PubMed: 10675325). These sites serve as the docking platform for the Specificity Protein 1 (Sp1) transcription factor, which plays a pivotal role in regulating housekeeping genes and those involved in cell cycle progression, apoptosis, and angiogenesis (NIH: PMC3073341). In many human cancers, including pancreatic and lung carcinomas, Sp1 is overexpressed or hyperactive, leading to the constitutive expression of oncogenic targets like VEGF and c-Myc (PubMed: 23536430). Therapeutic strategies targeting these DNA sequences involve small molecule ligands, such as Mithramycin A and its analogues, which bind to the minor groove of GC-rich DNA with high affinity. This binding sterically blocks Sp1 from accessing its consensus sites, thereby inhibiting the transcription of Sp1-dependent genes and inducing anti-tumor effects (PubMed: 21854854). Despite their potential, the widespread distribution of GC-rich sequences in the genome poses significant challenges for achieving high specificity and minimizing off-target toxicities (PubMed: 25151359). Research continues into more selective analogues, such as EC-8042, to improve the therapeutic window and reduce the systemic toxicity associated with traditional DNA-binding agents.
Small molecules bind to the minor groove of GC-rich DNA sequences, specifically the 5'-(G/C)GGGCGG(G/C)(G/C)-3' consensus motif, thereby sterically hindering the binding of the Sp1 transcription factor and inhibiting the expression of Sp1-dependent genes (PubMed: 21854854).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GC-rich DNA at Sp1 consensus promoter sites (GC box) (GC box).